aldosterone has been researched along with Hypertrophy in 83 studies
Hypertrophy: General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of low-dose oral spironolactone (SPIRO) in a rat model of hypertensive heart failure (spontaneously hypertensive heart failure rat) were compared with its effects when combined with captopril (CAP)." | 7.72 | Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. ( Bauer, JA; Ghosh, S; Holycross, BJ; Kambara, A; Kwiatkowski, P; McCune, SA; Schanbacher, B; Wung, P, 2003) |
| "Increased endothelin-1 (ET-1) or aldosterone may be associated with promotion of cardiovascular hypertrophy and fibrosis." | 7.71 | Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. ( Park, JB; Schiffrin, EL, 2002) |
| "To study the effects of Ca antagonists on hypertension induced cardiac and vascular hypertrophy, diltiazem, at the doses of 30 and 60 mg/kg, p." | 7.67 | [Effects of diltiazem on developing blood pressure and accompanying cardiac and vascular hypertrophy in SHR]. ( Inamasu, M; Iwasaki, HO; Morita, T; Nagao, T; Narita, H, 1985) |
| "Increased bioavailability of reactive oxygen species (ROS) has been implicated in the pathogenesis of mineralocorticoid hypertension." | 5.32 | NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. ( Park, JB; Park, MY; Park, YM; Suh, YL, 2004) |
| "Aldosterone caused a 27% increase in protein incorporation (EC(50) = 40 nmol/L) and a 29% increase in myocyte surface area compared with the vehicle control." | 5.32 | Aldosterone directly stimulates cardiac myocyte hypertrophy. ( Lorell, BH; Nakayama, M; O'Connell, TD; Okoshi, K; Okoshi, MP; Schuldt, AJ; Simpson, PC; Yan, X, 2004) |
| "The reactive fibrosis is thought to be related to MC excess, while cell loss and microscopic scarring may be secondary to enhanced potassium excretion or a cytotoxic effect of aldosterone." | 5.29 | Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride. ( Campbell, SE; Janicki, JS; Matsubara, BB; Weber, KT, 1993) |
| " Intracellular Na+ was measured using sodium-binding-benzofuran-isophthalate as a fluorescent sodium indicator, and cardiac hypertrophy was assessed using B-type natriuretic peptide transcription and (3)H-leucine incorporation." | 3.73 | Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. ( Abe, K; Nakao, K; Nakayama, M; Ogawa, H; Saito, Y; Sakamoto, T; Shono, M; Suzuki, S; Yamamuro, M; Yasue, H; Yoshimura, M, 2006) |
| "The effects of low-dose oral spironolactone (SPIRO) in a rat model of hypertensive heart failure (spontaneously hypertensive heart failure rat) were compared with its effects when combined with captopril (CAP)." | 3.72 | Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. ( Bauer, JA; Ghosh, S; Holycross, BJ; Kambara, A; Kwiatkowski, P; McCune, SA; Schanbacher, B; Wung, P, 2003) |
| "Increased endothelin-1 may be associated with elevation of blood pressure (BP) and promotion of vascular hypertrophy, especially in salt-sensitive hypertension." | 3.71 | ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. ( Park, JB; Schiffrin, EL, 2001) |
| "Increased endothelin-1 (ET-1) or aldosterone may be associated with promotion of cardiovascular hypertrophy and fibrosis." | 3.71 | Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. ( Park, JB; Schiffrin, EL, 2002) |
| "To study the effects of Ca antagonists on hypertension induced cardiac and vascular hypertrophy, diltiazem, at the doses of 30 and 60 mg/kg, p." | 3.67 | [Effects of diltiazem on developing blood pressure and accompanying cardiac and vascular hypertrophy in SHR]. ( Inamasu, M; Iwasaki, HO; Morita, T; Nagao, T; Narita, H, 1985) |
| "Objective- Pulmonary arterial hypertension is characterized by progressive pulmonary vascular remodeling and persistently elevated mean pulmonary artery pressures and pulmonary vascular resistance." | 1.51 | Transthoracic Pulmonary Artery Denervation for Pulmonary Arterial Hypertension. ( Huang, Y; Jing, ZC; Li, J; Liu, YW; Meng, J; Pan, HZ; Wang, PH; Xiang, L; Yang, J; Zhang, H; Zhang, XL, 2019) |
| "Aldosterone has been recognized as a risk factor for the development of chronic kidney disease (CKD)." | 1.43 | Epidermal growth factor receptor signaling mediates aldosterone-induced profibrotic responses in kidney. ( Ding, W; Gu, Y; Niu, J; Qiao, Z; Sheng, L; Yang, M; Zhang, M, 2016) |
| "A rat model of ventricular remodeling after myocardial infarction was established by left coronary artery ligation." | 1.42 | Cardioprotective effect of polydatin on ventricular remodeling after myocardial infarction in coronary artery ligation rats. ( Chen, C; Gao, J; Gao, Y; Guo, J; Wang, H; Wu, R, 2015) |
| "Obesity is a major risk factor for hypertension." | 1.38 | Increasing peripheral insulin sensitivity by protein tyrosine phosphatase 1B deletion improves control of blood pressure in obesity. ( Ali, MI; Belin de Chantemèle, EJ; Fulton, DJ; Mintz, JD; Rainey, WE; Stepp, DW; Tremblay, ML, 2012) |
| "Pre-treatment with eplerenone or Y27632 prevented the aldosterone-induced cell hypertrophy, actin polymerization, the increase in alpha-SMA expression and the increases of collagen type I, III, IV mRNA levels in RMCs." | 1.35 | Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells. ( Diah, S; Gang, L; Hamid, MR; Hitomi, H; Kimura, S; Nagai, Y; Nishiyama, A; Tamiya, T; Zhang, GX; Zhang, W, 2008) |
| "Increased bioavailability of reactive oxygen species (ROS) has been implicated in the pathogenesis of mineralocorticoid hypertension." | 1.32 | NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. ( Park, JB; Park, MY; Park, YM; Suh, YL, 2004) |
| "Aldosterone caused a 27% increase in protein incorporation (EC(50) = 40 nmol/L) and a 29% increase in myocyte surface area compared with the vehicle control." | 1.32 | Aldosterone directly stimulates cardiac myocyte hypertrophy. ( Lorell, BH; Nakayama, M; O'Connell, TD; Okoshi, K; Okoshi, MP; Schuldt, AJ; Simpson, PC; Yan, X, 2004) |
| "The reactive fibrosis is thought to be related to MC excess, while cell loss and microscopic scarring may be secondary to enhanced potassium excretion or a cytotoxic effect of aldosterone." | 1.29 | Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride. ( Campbell, SE; Janicki, JS; Matsubara, BB; Weber, KT, 1993) |
| "The effects of chronic administration of metoclopramide or bromocriptine (two drugs which act as antagonist and agonist of dopamine receptors) on the zona glomerulosa of captopril-treated rats administered maintenance doses of angiotensin II, were investigated by combined morphometric and biochemical techniques." | 1.27 | Long-term trophic effect of sodium restriction on the rat adrenal zona glomerulosa. II. The possible involvement of the inhibition of the dopaminergic system. ( Mazzocchi, G; Nussdorfer, GG; Rebuffat, P; Robba, C, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (44.58) | 18.7374 |
| 1990's | 12 (14.46) | 18.2507 |
| 2000's | 19 (22.89) | 29.6817 |
| 2010's | 13 (15.66) | 24.3611 |
| 2020's | 2 (2.41) | 2.80 |
| Authors | Studies |
|---|---|
| Montiel-Jaen, MG | 1 |
| Monsalvo-Villegas, A | 1 |
| Ávila, G | 1 |
| Stroedecke, K | 1 |
| Meinel, S | 1 |
| Markwardt, F | 1 |
| Kloeckner, U | 1 |
| Straetz, N | 1 |
| Quarch, K | 1 |
| Schreier, B | 1 |
| Kopf, M | 1 |
| Gekle, M | 1 |
| Grossmann, C | 1 |
| Huang, Y | 1 |
| Liu, YW | 1 |
| Pan, HZ | 1 |
| Zhang, XL | 1 |
| Li, J | 1 |
| Xiang, L | 1 |
| Meng, J | 1 |
| Wang, PH | 1 |
| Yang, J | 1 |
| Jing, ZC | 1 |
| Zhang, H | 1 |
| Gao, Y | 1 |
| Gao, J | 1 |
| Chen, C | 1 |
| Wang, H | 1 |
| Guo, J | 1 |
| Wu, R | 1 |
| Tarjus, A | 1 |
| Martínez-Martínez, E | 1 |
| Amador, C | 1 |
| Latouche, C | 1 |
| El Moghrabi, S | 1 |
| Berger, T | 1 |
| Mak, TW | 1 |
| Fay, R | 1 |
| Farman, N | 1 |
| Rossignol, P | 1 |
| Zannad, F | 1 |
| López-Andrés, N | 1 |
| Jaisser, F | 1 |
| Somanna, NK | 1 |
| Yariswamy, M | 1 |
| Garagliano, JM | 1 |
| Siebenlist, U | 1 |
| Mummidi, S | 1 |
| Valente, AJ | 1 |
| Chandrasekar, B | 1 |
| Araujo, CM | 1 |
| Hermidorff, MM | 1 |
| Amancio, Gde C | 1 |
| Lemos, Dda S | 1 |
| Silva, ME | 1 |
| de Assis, LV | 1 |
| Isoldi, MC | 1 |
| Sheng, L | 1 |
| Yang, M | 1 |
| Ding, W | 1 |
| Zhang, M | 1 |
| Niu, J | 1 |
| Qiao, Z | 1 |
| Gu, Y | 1 |
| Fan, C | 1 |
| Kawai, Y | 1 |
| Inaba, S | 1 |
| Arakawa, K | 1 |
| Katsuyama, M | 1 |
| Kajinami, K | 1 |
| Yasuda, T | 1 |
| Yabe-Nishimura, C | 1 |
| Konoshita, T | 1 |
| Miyamori, I | 2 |
| Diah, S | 1 |
| Zhang, GX | 1 |
| Nagai, Y | 1 |
| Zhang, W | 1 |
| Gang, L | 1 |
| Kimura, S | 1 |
| Hamid, MR | 1 |
| Tamiya, T | 1 |
| Nishiyama, A | 2 |
| Hitomi, H | 2 |
| Ishiguro, K | 1 |
| Hayashi, K | 1 |
| Sasamura, H | 1 |
| Sakamaki, Y | 1 |
| Itoh, H | 1 |
| Sakurabayashi-Kitade, S | 1 |
| Aoka, Y | 1 |
| Nagashima, H | 1 |
| Kasanuki, H | 1 |
| Hagiwara, N | 1 |
| Kawana, M | 1 |
| Arias-Loza, PA | 1 |
| Muehlfelder, M | 1 |
| Elmore, SA | 1 |
| Maronpot, R | 1 |
| Hu, K | 1 |
| Blode, H | 1 |
| Hegele-Hartung, C | 1 |
| Fritzemeier, KH | 1 |
| Ertl, G | 1 |
| Pelzer, T | 1 |
| Cetrullo, S | 1 |
| Facchini, A | 1 |
| Stanic, I | 1 |
| Tantini, B | 1 |
| Pignatti, C | 1 |
| Caldarera, CM | 1 |
| Flamigni, F | 1 |
| Yoshida, Y | 1 |
| Morimoto, T | 1 |
| Takaya, T | 1 |
| Kawamura, T | 1 |
| Sunagawa, Y | 1 |
| Wada, H | 1 |
| Fujita, M | 1 |
| Shimatsu, A | 1 |
| Kita, T | 1 |
| Hasegawa, K | 1 |
| Usher, MG | 1 |
| Duan, SZ | 1 |
| Ivaschenko, CY | 1 |
| Frieler, RA | 1 |
| Berger, S | 1 |
| Schütz, G | 1 |
| Lumeng, CN | 1 |
| Mortensen, RM | 1 |
| Grinevich, V | 1 |
| Jezova, D | 1 |
| Gambaryan, S | 1 |
| Illarionova, A | 1 |
| Kolleker, A | 1 |
| Seeburg, PH | 1 |
| Schwarz, MK | 1 |
| Sherajee, SJ | 1 |
| Fujita, Y | 1 |
| Rafiq, K | 1 |
| Nakano, D | 1 |
| Mori, H | 1 |
| Masaki, T | 1 |
| Hara, T | 1 |
| Kohno, M | 1 |
| Belin de Chantemèle, EJ | 1 |
| Ali, MI | 1 |
| Mintz, JD | 1 |
| Rainey, WE | 1 |
| Tremblay, ML | 1 |
| Fulton, DJ | 1 |
| Stepp, DW | 1 |
| Briet, M | 1 |
| Schiffrin, EL | 4 |
| Kambara, A | 1 |
| Holycross, BJ | 1 |
| Wung, P | 1 |
| Schanbacher, B | 1 |
| Ghosh, S | 1 |
| McCune, SA | 1 |
| Bauer, JA | 1 |
| Kwiatkowski, P | 1 |
| Song, J | 1 |
| Knepper, MA | 1 |
| Verbalis, JG | 1 |
| Ecelbarger, CA | 1 |
| PRUNTY, FT | 1 |
| MCSWINEY, RR | 1 |
| MILLS, IH | 1 |
| HARDY, JD | 1 |
| WEBB, WR | 1 |
| SULYA, LL | 1 |
| McCAA, C | 1 |
| WEISZ, P | 1 |
| KEMENY, V | 1 |
| CARR, HE | 1 |
| CURTIS, GW | 1 |
| THORN, GW | 1 |
| Park, YM | 1 |
| Park, MY | 1 |
| Suh, YL | 1 |
| Park, JB | 3 |
| Tsybouleva, N | 1 |
| Zhang, L | 1 |
| Chen, S | 1 |
| Patel, R | 1 |
| Lutucuta, S | 1 |
| Nemoto, S | 1 |
| DeFreitas, G | 1 |
| Entman, M | 1 |
| Carabello, BA | 1 |
| Roberts, R | 1 |
| Marian, AJ | 1 |
| Nakamura, S | 1 |
| Yoshimura, M | 2 |
| Nakayama, M | 3 |
| Ito, T | 1 |
| Mizuno, Y | 1 |
| Harada, E | 1 |
| Sakamoto, T | 2 |
| Saito, Y | 2 |
| Nakao, K | 2 |
| Yasue, H | 2 |
| Ogawa, H | 2 |
| Okoshi, MP | 1 |
| Yan, X | 1 |
| Okoshi, K | 1 |
| Schuldt, AJ | 1 |
| O'Connell, TD | 1 |
| Simpson, PC | 1 |
| Lorell, BH | 1 |
| Neuberger, HR | 1 |
| Schotten, U | 1 |
| Verheule, S | 1 |
| Eijsbouts, S | 1 |
| Blaauw, Y | 1 |
| van Hunnik, A | 1 |
| Allessie, M | 1 |
| Yamamuro, M | 1 |
| Abe, K | 1 |
| Shono, M | 1 |
| Suzuki, S | 1 |
| Neves, MF | 1 |
| Amiri, F | 1 |
| Virdis, A | 1 |
| Diep, QN | 1 |
| Franco, V | 1 |
| Chen, YF | 1 |
| Feng, JA | 1 |
| Li, P | 1 |
| Wang, D | 1 |
| Hasan, E | 1 |
| Oparil, S | 1 |
| Perry, GJ | 1 |
| Colella, M | 1 |
| Grisan, F | 1 |
| Robert, V | 1 |
| Turner, JD | 1 |
| Thomas, AP | 1 |
| Pozzan, T | 1 |
| Purjesz, I | 1 |
| Hüttner, I | 1 |
| Rafestin-Oblin, ME | 1 |
| Claire, M | 1 |
| Michaud, A | 1 |
| Corvol, P | 1 |
| Dunlap, NE | 2 |
| Grizzle, WE | 2 |
| Sokol, HW | 1 |
| Möhring, J | 1 |
| Rebuffat, P | 9 |
| Belloni, AS | 3 |
| Musajo, FG | 3 |
| Rocco, S | 1 |
| Markowska, A | 1 |
| Mazzocchi, G | 10 |
| Nussdorfer, GG | 10 |
| Hatakeyama, H | 1 |
| Fujita, T | 1 |
| Takeda, Y | 1 |
| Takeda, R | 2 |
| Yamamoto, H | 1 |
| Nowak, KW | 1 |
| Tortorella, C | 1 |
| Gottardo, G | 3 |
| Campbell, SE | 1 |
| Janicki, JS | 1 |
| Matsubara, BB | 1 |
| Weber, KT | 1 |
| Terzi, F | 1 |
| Cheval, L | 1 |
| Barlet-Bas, C | 1 |
| Younes-Ibrahim, M | 1 |
| Buffin-Meyer, B | 1 |
| Burtin, M | 1 |
| Beaufils, H | 1 |
| Marsy, S | 1 |
| Girolami, JP | 1 |
| Kleinknecht, C | 1 |
| Doucet, A | 1 |
| Hastings, NB | 1 |
| McEwen, BS | 1 |
| Nishijo, N | 1 |
| Takamine, S | 1 |
| Sugiyama, F | 1 |
| Kimoto, K | 1 |
| Taniguchi, K | 1 |
| Horiguchi, H | 1 |
| Ogata, T | 1 |
| Murakami, K | 1 |
| Fukamizu, A | 1 |
| Yagami, K | 1 |
| Duprez, D | 1 |
| De Buyzere, M | 1 |
| Rietzschel, ER | 1 |
| Clement, DL | 1 |
| Hadjikyriacou, MI | 1 |
| Davaris, P | 1 |
| Papacharalampous, NX | 1 |
| Loeschke, K | 1 |
| Müller, OA | 1 |
| Skogseid, B | 1 |
| Larsson, C | 1 |
| Lindgren, PG | 1 |
| Kvanta, E | 1 |
| Rastad, J | 1 |
| Theodorsson, E | 1 |
| Wide, L | 1 |
| Wilander, E | 1 |
| Oberg, K | 1 |
| Neri, G | 2 |
| Andreis, PG | 2 |
| Hamm, LL | 1 |
| Vehaskari, VM | 2 |
| Herndon, J | 1 |
| Robba, C | 5 |
| Narita, H | 1 |
| Nagao, T | 1 |
| Inamasu, M | 1 |
| Iwasaki, HO | 1 |
| Morita, T | 1 |
| Matsuo, K | 1 |
| Kawai, K | 1 |
| Tsuchiyama, H | 1 |
| Ueki, Y | 1 |
| Malendowicz, LK | 2 |
| Imai, M | 1 |
| Yabuta, K | 1 |
| Murata, H | 1 |
| Takita, S | 1 |
| Ohbe, Y | 1 |
| Sokabe, H | 1 |
| Okano, M | 1 |
| Trygstad, CW | 1 |
| Mangos, JA | 1 |
| Bloodworth, JM | 1 |
| Lobeck, CC | 1 |
| Goodman, AD | 1 |
| Vagnucci, AH | 1 |
| Hartroft, PM | 1 |
| Desmit, EM | 1 |
| Cost, WS | 1 |
| Brown, JJ | 1 |
| Fraser, R | 1 |
| Lever, AF | 1 |
| Robertson, JI | 1 |
| Arant, BS | 1 |
| Brackett, NC | 1 |
| Young, RB | 1 |
| Still, WJ | 1 |
| White, MG | 1 |
| Ramanathan, K | 1 |
| Gantt, C | 1 |
| Grossman, A | 1 |
| Modlinger, RS | 1 |
| Nicolis, GL | 1 |
| Krakoff, LR | 1 |
| Gabrilove, JL | 1 |
| Nielsen, I | 1 |
| Jacobsen, JG | 1 |
| Olesen, KH | 1 |
| Morimoto, S | 1 |
| Kuroda, M | 1 |
| Murakami, M | 1 |
| Kono, T | 1 |
| Dahl, V | 1 |
| Bergadá, C | 1 |
| Pike, RL | 1 |
| Ganguli, MC | 1 |
| Gall, G | 1 |
| Vaitukaitis, J | 1 |
| Haddow, JE | 1 |
| Klein, R | 1 |
| Ushkalov, AF | 1 |
| Pal, SP | 1 |
| Reid, IA | 1 |
| McDonald, IR | 1 |
| Euchenhofer, M | 1 |
| Streicher, E | 1 |
| Würz, H | 1 |
| Meurer, KA | 1 |
| Steiner, B | 1 |
| Dürr, F | 1 |
| Kaufmann, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial[NCT02948998] | Phase 4 | 260 participants (Anticipated) | Interventional | 2018-05-14 | Not yet recruiting | ||
| Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy[NCT00879060] | Phase 4 | 53 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Specific variables of collagen turnover markers that will be evaluated include markers of collagen synthesis (PINP, PIIINP), and marker of collagen degradation (ICTP). A two-sample t-test was used to compare the differences between these collagen turnover markers at baseline and the absolute differences in change from baseline to 12 months of follow-up. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | micrograms/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline (PINP) | 12 Months (PINP) | Baseline (PIIINP) | 12 Months (PIIINP) | Baseline (ICTP) | 12 Months (ICTP) | |
| Placebo Control | 2.1 | 0.6 | 4.5 | 1.6 | 2.5 | -2.3 |
| Spironolactone | 2.1 | 0.7 | 4.7 | 2.0 | 2.2 | 2.7 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | millimeters (Mean) | |
|---|---|---|
| Left Atrial Dimension (Baseline) | Left Atrial Dimension (12-Month Follow-Up) | |
| Placebo Control | 41 | 40 |
| Spironolactone | 40 | 40 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic (LVED) cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | mm/m^2 (Mean) | |
|---|---|---|
| LVED Cavity Size (Baseline) | LVED Cavity Size (12-Month Follow-Up) | |
| Placebo Control | 145 | 146 |
| Spironolactone | 133 | 129 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | millimeters (Mean) | |
|---|---|---|
| Maximum Left Ventricular Wall Thickness (Baseline) | Maximum Left Ventricular Wall Thickness (12-Month Follow-Up) | |
| Placebo Control | 21 | 19 |
| Spironolactone | 22 | 22 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Percentage of Total LV Mass (Mean) | |
|---|---|---|
| LGE Assessment of Myocardial Fibrosis (Baseline) | LGE Assessment of Myocardial Fibrosis (12-Month Follow-Up) | |
| Placebo Control | 2.5 | 2.8 |
| Spironolactone | 1.1 | 1.8 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to determine if spironolactone improves a subject's functional capacity during exercise (peak oxygen consumption levels/peak VO2). Peak VO2 levels were measured in ml/kg/min. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | ml/kg/min (Mean) | |
|---|---|---|
| Peak VO2 (Baseline) | Peak VO2 (12-Month Follow-Up) | |
| Placebo Control | 28 | 29 |
| Spironolactone | 30 | 29 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to assess heart failure symptoms according to the New York Heart Association (NYHA) functional class, which is an estimate of a patients functional ability. The NYHA functional classes include: Class I (no limitation of physical activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (unable to carry out any physical acitivity without discomfort). (NCT00879060)
Timeframe: Time points were measured at Baseline and again at 12 months (follow-up)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| NYHA Class (Baseline) | NYHA Class (12-Month Follow Up) | |
| Placebo Control | 1.5 | 1.6 |
| Spironolactone | 1.6 | 1.7 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to measure indices of diastolic function by Tissue Doppler Echocardiography using the Septal E/e' ratio. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Ratio (Mean) | |
|---|---|---|
| Diastolic Function (Baseline) | Diastolic Function (12-month Follow-Up) | |
| Placebo Control | 15 | 13 |
| Spironolactone | 14 | 13 |
3 reviews available for aldosterone and Hypertrophy
| Article | Year |
|---|---|
Vascular actions of aldosterone.
Topics: Adipocytes; Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Vessels; Cardiovasc | 2013 |
Aldosterone and vascular damage.
Topics: Adrenal Cortex; Aldosterone; Arteries; Autonomic Nervous System; Baroreflex; Body Water; Compliance; | 2000 |
[Recent knowledge of diseases with abnormal aldosterone secretion].
Topics: Addison Disease; Adolescent; Adrenal Cortex Hormones; Adrenal Gland Neoplasms; Adult; Aldosterone; A | 1971 |
80 other studies available for aldosterone and Hypertrophy
| Article | Year |
|---|---|
Modulating ALDH2 reveals a differential dependence on ROS for hypertrophy and SR Ca
Topics: Aldehyde Dehydrogenase, Mitochondrial; Aldosterone; Animals; Biopterins; Calcium; Homeostasis; Hyper | 2021 |
The mineralocorticoid receptor leads to increased expression of EGFR and T-type calcium channels that support HL-1 cell hypertrophy.
Topics: Aldosterone; Animals; Calcium Channels, T-Type; Cardiovascular System; Cell Line; ErbB Receptors; Fe | 2021 |
Transthoracic Pulmonary Artery Denervation for Pulmonary Arterial Hypertension.
Topics: Adolescent; Aldosterone; Animals; Child, Preschool; Cytokines; Disease Progression; Female; Fibrosis | 2019 |
Cardioprotective effect of polydatin on ventricular remodeling after myocardial infarction in coronary artery ligation rats.
Topics: Aldosterone; Animals; Antioxidants; Captopril; Collagen; Coronary Occlusion; Coronary Vessels; Endot | 2015 |
Neutrophil Gelatinase-Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids.
Topics: Acute-Phase Proteins; Aldosterone; Animals; Aorta; Cardiomyopathy, Hypertrophic; Cells, Cultured; Cy | 2015 |
Aldosterone-induced cardiomyocyte growth, and fibroblast migration and proliferation are mediated by TRAF3IP2.
Topics: Adaptor Proteins, Signal Transducing; Aldosterone; Animals; Cell Movement; Cell Proliferation; Cells | 2015 |
Rapid effects of aldosterone in primary cultures of cardiomyocytes - do they suggest the existence of a membrane-bound receptor?
Topics: A Kinase Anchor Proteins; Aldosterone; Animals; Atrial Natriuretic Factor; Cyclic AMP; Egtazic Acid; | 2016 |
Epidermal growth factor receptor signaling mediates aldosterone-induced profibrotic responses in kidney.
Topics: Aldosterone; Animals; Cell Line; Cell Movement; Cell Proliferation; ErbB Receptors; Erlotinib Hydroc | 2016 |
Synergy of aldosterone and high salt induces vascular smooth muscle hypertrophy through up-regulation of NOX1.
Topics: Aldosterone; Animals; Aorta; Cell Line; Dose-Response Relationship, Drug; Drug Synergism; Hypertroph | 2008 |
Aldosterone induces myofibroblastic transdifferentiation and collagen gene expression through the Rho-kinase dependent signaling pathway in rat mesangial cells.
Topics: Aldosterone; Amides; Animals; Cell Transdifferentiation; Collagen; Eplerenone; Gene Expression Regul | 2008 |
"Pulse" treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2009 |
Aldosterone blockade by Spironolactone improves the hypertensive vascular hypertrophy and remodeling in angiotensin II overproducing transgenic mice.
Topics: Aldosterone; Angiotensin II; Animals; Female; Hyperplasia; Hypertension; Hypertrophy; Male; Mice; Mi | 2009 |
Differential effects of 17beta-estradiol and of synthetic progestins on aldosterone-salt-induced kidney disease.
Topics: Aldosterone; Androstenes; Animals; Blood Pressure; Epithelial Sodium Channels; Estradiol; Female; Hy | 2009 |
Difluoromethylornithine inhibits hypertrophic, pro-fibrotic and pro-apoptotic actions of aldosterone in cardiac cells.
Topics: Aldosterone; Animals; Apoptosis; Biogenic Polyamines; Cells, Cultured; Eflornithine; Fibrosis; Gene | 2010 |
Aldosterone signaling associates with p300/GATA4 transcriptional pathway during the hypertrophic response of cardiomyocytes.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Chlorocebus aethiops; COS Cells; Disease Models, An | 2010 |
Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Fibrosis; Heart; Hypert | 2010 |
Hypertrophy and altered activity of the adrenal cortex in Homer 1 knockout mice.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Aldosterone; Animals; Carrier Proteins; Corticosterone; | 2011 |
Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor.
Topics: Aldosterone; Animals; Aorta, Thoracic; Blood Pressure; Cells, Cultured; Chimera; Eplerenone; Glucose | 2012 |
Increasing peripheral insulin sensitivity by protein tyrosine phosphatase 1B deletion improves control of blood pressure in obesity.
Topics: Adrenergic alpha-1 Receptor Agonists; Albuminuria; Aldosterone; Animals; Blood Pressure; Dose-Respon | 2012 |
Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure.
Topics: Administration, Oral; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriur | 2003 |
Increased renal ENaC subunit and sodium transporter abundances in streptozotocin-induced type 1 diabetes.
Topics: Aldosterone; Animals; Aquaporin 1; Aquaporin 2; Aquaporin 3; Aquaporin 6; Aquaporins; Blood Glucose; | 2003 |
Biological effects of aldosterone with especial reference to man.
Topics: Addison Disease; Adrenal Cortex; Adrenal Cortex Diseases; Adrenal Cortex Hormones; Adrenal Insuffici | 1955 |
Renal hypertension with elevated aldosterone. Case due to muscular hypertrophy cured by nephrectomy with decline of aldosterone levels to normal.
Topics: Aldosterone; Humans; Hypertension; Hypertension, Renal; Hypertrophy; Kidney; Nephrectomy | 1963 |
ALDOSTERONE PRODUCTION OF COMPENSATED HYPERTROPHIC ADRENALS.
Topics: Adrenal Gland Diseases; Adrenal Glands; Aldosterone; Corticosterone; Hyperplasia; Hypertrophy; Metab | 1963 |
A CLINICAL-BIOCHEMICAL-HISTOLOGIC CORRELATION IN HYPERADRENOCORTICISM CAUSED BY ACQUIRED ADRENOCORTICAL HYPERPLASIA.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Adrenal Gland Diseases; Adrenalectomy; Adrenocortical Hype | 1964 |
NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats.
Topics: Acetophenones; Aldosterone; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Collagen; Fibro | 2004 |
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells | 2004 |
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells | 2004 |
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells | 2004 |
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.
Topics: Aged; Aldosterone; Animals; beta Catenin; Biomarkers; Cadherins; Cardiomyopathy, Hypertrophic; Cells | 2004 |
Possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heart.
Topics: Adult; Aged; Aldosterone; Animals; Blotting, Southern; Cardiac Catheterization; Cell Size; Cells, Cu | 2004 |
Aldosterone directly stimulates cardiac myocyte hypertrophy.
Topics: Aldosterone; Animals; Animals, Newborn; Cells, Cultured; Culture Media, Serum-Free; Dexamethasone; E | 2004 |
Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Fibrillation; Atrial Natriuretic Factor; Cardiac Pacing | 2005 |
Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium.
Topics: Aldosterone; Amides; Animals; Benzofurans; Cells, Cultured; Eplerenone; Hemodynamics; Hypertrophy; I | 2006 |
Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
Topics: Aldosterone; Angiotensin II; Animals; Aorta; Collagen; Ectodysplasins; Fibrosis; Heart; Hypertension | 2005 |
Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Eplerenone; Heart; Hy | 2006 |
Ca2+ oscillation frequency decoding in cardiac cell hypertrophy: role of calcineurin/NFAT as Ca2+ signal integrators.
Topics: Aldosterone; Angiotensin II; Animals; Calcineurin; Calcium; Cells, Cultured; DNA, Complementary; Hyp | 2008 |
The effect of prolonged water loading on the function of the adrenal zona glomerulosa.
Topics: Adrenal Gland Diseases; Adrenal Glands; Aldosterone; Animals; Hypertrophy; In Vitro Techniques; Isot | 1967 |
Mineralocorticoid receptors during normal kidney growth and compensatory renal hypertrophy.
Topics: Adrenalectomy; Aldosterone; Animals; Dexamethasone; Hypertrophy; Kidney; Male; Nephrectomy; Rats; Re | 1981 |
Golden Syrian hamsters: a new experimental model for adrenal compensatory hypertrophy.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Aldosterone; Animals; Cricetinae; Dexamethasone; Diseas | 1984 |
Aldosterone blocks adrenal compensatory hypertrophy in the rat.
Topics: Adrenal Glands; Adrenalectomy; Adrenocorticotropic Hormone; Aldosterone; Animals; Dexamethasone; Fee | 1984 |
Morphological correlates of renin and aldosterone secretion in the Brattleboro rat.
Topics: Adrenal Cortex; Aldosterone; Animals; Arginine Vasopressin; Cytoplasmic Granules; Diabetes Insipidus | 1982 |
Evidence that endogenous somatostatin (SRIF) exerts an inhibitory control on the function and growth of rat adrenal zona glomerulosa. The possible involvement of zona medullaris as a source of endogenous SRIF.
Topics: Adrenal Cortex; Adrenalectomy; Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Animals; At | 1994 |
Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells.
Topics: Aldosterone; Amino Acid Sequence; Angiotensin II; Base Sequence; Cells, Cultured; Cytochrome P-450 C | 1994 |
Evidence that endogenous vasoactive intestinal peptide (VIP) plays a role in the maintenance of the growth and steroidogenic capacity of rat adrenal zona glomerulosa.
Topics: Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Animals; Blood Pressure; Corticosterone; H | 1994 |
Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride.
Topics: Aldosterone; Amiloride; Animals; Cardiomyopathies; Cicatrix; Collagen; Disease Models, Animal; Drug | 1993 |
Na-K-ATPase along rat nephron after subtotal nephrectomy: effect of enalapril.
Topics: Aldosterone; Animals; Bradykinin; Enalapril; Hypertrophy; Kidney Tubules; Male; Nephrectomy; Nephron | 1996 |
Characterization of adrenal hormone binding sites in the prairie vole.
Topics: Adrenalectomy; Adrenocorticotropic Hormone; Aldosterone; Androstanols; Animals; Arginine Vasopressin | 1997 |
Vascular remodeling in hypertensive transgenic mice.
Topics: Aldosterone; Animals; Aorta, Abdominal; Aorta, Thoracic; Arteriosclerosis; Blood Pressure; Disease M | 1999 |
ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats.
Topics: Aldosterone; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Body Weight; Dansyl Compounds; | 2001 |
Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1.
Topics: Aldosterone; Animals; Antihypertensive Agents; Aorta; Aortic Diseases; Blood Pressure; Body Weight; | 2002 |
Histochemical changes effected by aldosterone on compensatory renal growth in the rat.
Topics: Adenosine Triphosphatases; Aldosterone; Alkaline Phosphatase; Animals; Electron Transport Complex IV | 1976 |
Hormones and the stimulated sodium transport in cecum hypertrophy.
Topics: Adrenalectomy; Aldosterone; Animals; Biological Transport; Cecal Diseases; Diabetes Mellitus; Ethyle | 1975 |
Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1.
Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Adult; Aged; Aldosterone; Chr | 1992 |
Effects of prolonged treatment with adrenocorticotropin on the morphology and function of rat adrenocortical autotransplants.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Aldosterone; Animals; Chromatography, High Pressure Liq | 1991 |
Compensatory hypertrophy and adaptation in the cortical collecting duct.
Topics: Adaptation, Physiological; Adrenalectomy; Aldosterone; Animals; Biological Transport; Epidermal Grow | 1991 |
Role of mineralocorticoids in adaptation of rabbit cortical collecting duct after loss of renal mass.
Topics: Adaptation, Physiological; Adrenalectomy; Aldosterone; Animals; Dose-Response Relationship, Drug; Fe | 1991 |
Stereological and functional investigations on isolated adrenocortical cells. III. Zona glomerulosa cells of chronically ACTH-treated rats.
Topics: 18-Hydroxycorticosterone; Adrenocorticotropic Hormone; Aldosterone; Animals; Corticosterone; Desoxyc | 1990 |
Further studies on the inhibitory effects of somatostatin on the growth and steroidogenic capacity of rat adrenal zona glomerulosa.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Aldosterone; Animals; Captopril; Corticosterone; Hypert | 1986 |
[Effects of diltiazem on developing blood pressure and accompanying cardiac and vascular hypertrophy in SHR].
Topics: Aldosterone; Animals; Aorta; Aortic Diseases; Benzazepines; Cardiomegaly; Diltiazem; Hindlimb; Hyper | 1985 |
Glucocorticoid-suppressible hyperaldosteronism. Ultrastructural observation of a case.
Topics: Adrenal Cortex; Aldosterone; Dexamethasone; Endoplasmic Reticulum; Female; Humans; Hyperaldosteronis | 1985 |
Short- and long-term effects of ACTH on the adrenal zona glomerulosa of the rat. A coupled stereological and enzymological study.
Topics: 3-Hydroxysteroid Dehydrogenases; Adrenal Cortex; Adrenocorticotropic Hormone; Aldosterone; Animals; | 1986 |
Long-term trophic effect of sodium restriction on the rat adrenal zona glomerulosa. I. Its partial independence of the renin-angiotensin system.
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Animals; Captopril; Diet, Sodium-Restricted; Endoplasmi | 1988 |
Long-term trophic effect of sodium restriction on the rat adrenal zona glomerulosa. II. The possible involvement of the inhibition of the dopaminergic system.
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Animals; Bromocriptine; Captopril; Diet, Sodium-Restric | 1988 |
Long-term stimulatory effect of neuropeptide-Y on the growth and steroidogenic capacity of rat adrenal zona glomerulosa.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Aldosterone; Angiotensin II; Animals; Corticosterone; Hyper | 1988 |
Long-term trophic action of alpha-melanocyte-stimulating hormone on the zona glomerulosa of the rat adrenal cortex.
Topics: Adrenal Cortex; Aldosterone; Animals; Corticosterone; Hypertrophy; Male; Melanocyte-Stimulating Horm | 1986 |
A case of Bartter's syndrome with abnormal renin response to salt load.
Topics: Adrenal Gland Diseases; Aldosterone; Alkalosis; Angiotensin II; Blood Pressure; Child; Diet; Dwarfis | 1969 |
[Study on the renin-angiotensin-aldosterone system. Evaluation of the dynamics of renal renin and adrenal cortex aldosterone production in the chronic stage of Goldblatt's rats].
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Animals; Blood Pressure; Chromatography, Thin Layer; Ch | 1967 |
A sibship with Bartter's syndrome: failure of total adrenalectomy to correct the potassium wasting.
Topics: Adrenal Gland Diseases; Adrenalectomy; Aldosterone; Alkalosis; Angiotensin II; Child, Preschool; Ery | 1969 |
Pathogenesis of Bartter's syndrome.
Topics: Adrenal Gland Diseases; Adrenocorticotropic Hormone; Albumins; Aldosterone; Alkalosis; Angiotensin I | 1969 |
An unusual type of hypokalaemic alkalosis with a disturbance of renin and aldosterone.
Topics: Adolescent; Adrenal Cortex Hormones; Albumins; Aldosterone; Alkalosis; Angiotensin II; Creatinine; D | 1970 |
Case studies of siblings with juxtaglomerular hyperplasia and secondary aldosteronism associated with severe azotemia and renal rickets--Bartter's syndrome or disease?
Topics: Aldosterone; Alkalosis; Angiotensin II; Bone Diseases; Child; Child, Preschool; Humans; Hyperaldoste | 1970 |
Bartter's syndrome. A manifestation of renal tubular defects.
Topics: Adult; Aldosterone; Alkalosis; Angiotensin II; Bicarbonates; Chlorides; Diet Therapy; Diet, Sodium-R | 1972 |
Six year follow-up of a child with Bartter syndrome.
Topics: Aldosterone; Alkalosis; Angiotensin II; Biopsy; Blood Pressure; Child, Preschool; Diet Therapy; Fema | 1973 |
Some observations on the pathogenesis of Bartter's syndrome.
Topics: Adult; Aldosterone; Alkalosis; Angiotensin II; Blood Volume; Drug Therapy, Combination; Humans; Hype | 1973 |
On the pathogenesis of the secondary hyperaldosteronism of the Bartter syndrome.
Topics: Adolescent; Adult; Aldosterone; Alkalosis; Biopsy; Diet Therapy; Female; Humans; Hyperaldosteronism; | 1973 |
Renal tubular acidosis, presenting as a syndrome resembling Bartter's syndrome, in a patient with arachnodactyly.
Topics: Acidosis, Renal Tubular; Adult; Aldosterone; Alkalosis; Biopsy; Humans; Hyperaldosteronism; Hyperpla | 1973 |
[Excretion of labile acid aldosterone in congenital adrenal hypertrophy].
Topics: Adolescent; Adrenal Gland Diseases; Adrenal Hyperplasia, Congenital; Adult; Aldosterone; Child; Huma | 1969 |
Sodium requirement of the pregnant rat.
Topics: Adrenocortical Hyperfunction; Aldosterone; Animals; Deficiency Diseases; Female; Hyperplasia; Hypert | 1970 |
Erythrocyte Na flux in a patient with Bartter's syndrome.
Topics: Aldosterone; Alkalosis; Ammonium Chloride; Biological Transport; Biological Transport, Active; Cell | 1971 |
[Study of the juxtaglomerular apparatus in various forms of experimental hypertension].
Topics: Aldosterone; Animals; Arteries; Blood Pressure; Constriction; Hyperplasia; Hypertension; Hypertensio | 1967 |
Bilateral adrenalectomy and steroid replacement in the marsupial Trichosurus vulpecula.
Topics: Adrenal Gland Diseases; Adrenal Glands; Adrenalectomy; Aldosterone; Animals; Bicarbonates; Chlorides | 1968 |
[Hypokalemic metabolic alkalosis].
Topics: Acid-Base Equilibrium; Adrenal Gland Diseases; Adrenocortical Hyperfunction; Adult; Aldosterone; Alk | 1969 |